<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CARIMUNE  NANOFILTERED- human immunoglobulin g injection, powder, lyophilized, for solution </strong><br>CSL Behring AG<br></p></div>
<h1>Immune Globulin Intravenous (Human) <br>Carimune<span class="Sup">®</span> NF, Nanofiltered</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DL"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">CSL Behring</span></p>
<p><span class="Bold">Lyophilized Preparation</span></p>
<p><span class="Bold">R<span class="Sub">X</span> only</span></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-2"></a><p></p>
<h1><span class="Emphasis">WARNING: <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">THROMBOSIS</span>, RENAL DYSFUNCTION, or <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">ACUTE RENAL FAILURE</span></span></h1>
<ul class="Disc">
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> may occur with immune globulin products<span class="Sup">1-8</span>, including Carimune NF.  Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors.  <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> may occur in the absence of known risk factors (see <a href="#<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>">PRECAUTIONS: <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></a>, <a href="#IFP">Information for Patients</a>).</span></li>
<li><span class="Bold">Renal dysfunction, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, osmotic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur in predisposed patients with immune globulin intravenous (IGIV) products<span class="Sup">9–14</span>, including Carimune NF.  Patients predisposed to renal dysfunction include those with any degree of pre-existing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, age greater than 65, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="441532" conceptname="Monoclonal paraproteinemia">paraproteinemia</span>, or patients receiving known nephrotoxic drugs.  Renal dysfunction and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> occur more commonly in patients receiving IGIV products containing sucrose.  Carimune NF contains sucrose.</span></li>
<li><span class="Bold">For patients at risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, renal dysfunction or <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, administer Carimune NF at the minimum dose and infusion rate practicable.  Ensure adequate hydration in patients before administration.  Monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> and assess blood viscosity in patients at risk for hyperviscosity (see <a href="#DA">DOSAGE AND ADMINISTRATION</a>, and <a href="#<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>">PRECAUTIONS: <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></a>).</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Carimune<span class="Sup">®</span> NF, Nanofiltered, Immune Globulin Intravenous (Human), is a sterile, highly purified polyvalent antibody product containing in concentrated form all the IgG antibodies which regularly occur in the donor population.<span class="Sup">15</span>  This immunoglobulin preparation is produced by <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> alcohol fractionation from the plasma of US donors. Part of the fractionation may be performed by another US-licensed manufacturer. Carimune<span class="Sup">®</span> NF is made suitable for intravenous use by treatment at acid pH in the presence of trace amounts of pepsin.<span class="Sup">16,17</span>  The manufacturing process by which Carimune<span class="Sup">®</span> NF is prepared from plasma consists of fractionation and purification steps that comprise filtrations in the presence of filter aids. Four of these steps were validated for virus elimination of both enveloped and non-enveloped viruses. Additionally, the manufacturing process was investigated for its capacity to decrease the infectivity of an experimental agent of transmissible spongiform <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> (TSE), considered as a model for the vCJD and CJD agents.<span class="Sup">18</span>  To complement the existing virus elimination / inactivation mechanism in the Carimune<span class="Sup">®</span> NF manufacturing process, nanofiltration (removing viruses via size-exclusion) was introduced as an additional virus removal step into the manufacturing process.<span class="Sup">19,20</span>  Nanofiltration is performed prior to the viral inactivation step (pH 4 in presence of pepsin) in order to reduce the potential viral load before inactivation is performed. Treatment with pepsin at pH 4 rapidly inactivates enveloped viruses.<span class="Sup">21</span></p>
<p>The Carimune<span class="Sup">®</span> NF manufacturing process provides a significant virus reduction capacity as shown in <span class="Italics">in vitro</span> studies. The results, summarized in Table 1, demonstrate virus clearance during Carimune<span class="Sup">®</span> NF manufacturing using model viruses for lipid enveloped and non-enveloped viruses.</p>
<a name="table1"></a><table width="90%">
<caption><span>Table 1: Virus Elimination and Inactivation</span></caption>
<col align="left" valign="top" width="6%">
<col align="left" valign="top" width="16%">
<col align="left" valign="top" width="13%">
<col align="left" valign="top" width="13%">
<col align="left" valign="top" width="13%">
<col align="left" valign="top" width="13%">
<col align="left" valign="top" width="13%">
<col align="left" valign="top" width="13%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left" colspan="2">Virus</th>
<th class="Rrule" align="left">HIV</th>
<th class="Rrule" align="left">BVDV</th>
<th class="Rrule" align="left">PRV</th>
<th class="Rrule" align="left">SFV</th>
<th class="Rrule" align="left">SV</th>
<th class="Rrule" align="left">BEV</th>
</tr></thead>
<tfoot>
<tr class="First">
<td align="left">HIV: </td>
<td align="left" colspan="7">Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus, model for HIV 1 and HIV 2</td>
</tr>
<tr>
<td align="left">BVDV: </td>
<td align="left" colspan="7">Bovine viral <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> virus, model for HCV (<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C virus)</td>
</tr>
<tr>
<td align="left">PRV: </td>
<td align="left" colspan="7">Pseudorabies virus, model for large, enveloped DNA viruses (e.g., herpes virus)</td>
</tr>
<tr>
<td align="left">SFV:</td>
<td align="left" colspan="7">Semliki Forest virus, model for HCV</td>
</tr>
<tr>
<td align="left">SV: </td>
<td align="left" colspan="7">Sindbis virus, model for HCV</td>
</tr>
<tr>
<td align="left">BEV: </td>
<td align="left" colspan="7">Bovine enterovirus, model for HAV (<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> A virus)</td>
</tr>
<tr class="Last">
<td align="left">nt: </td>
<td align="left" colspan="7">not tested</td>
</tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left" colspan="2">Genome </td>
<td class="Rrule" align="left">RNA</td>
<td class="Rrule" align="left">RNA</td>
<td class="Rrule" align="left">DNA</td>
<td class="Rrule" align="left">RNA</td>
<td class="Rrule" align="left">RNA</td>
<td class="Rrule" align="left">RNA</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2">Envelope</td>
<td class="Rrule" align="left">Yes</td>
<td class="Rrule" align="left">Yes</td>
<td class="Rrule" align="left">Yes</td>
<td class="Rrule" align="left">Yes</td>
<td class="Rrule" align="left">Yes</td>
<td class="Rrule" align="left">No</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2">Size (nm) <br>   </td>
<td class="Rrule" align="left">80–100</td>
<td class="Rrule" align="left">40–60</td>
<td class="Rrule" align="left">120–200</td>
<td class="Rrule" align="left">50–70</td>
<td class="Rrule" align="left">50–70</td>
<td class="Rrule" align="left">28–30</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2">Fractionation &amp; Depth filtration</td>
<td class="Rrule" align="left">15.5</td>
<td class="Rrule" align="left">nt</td>
<td class="Rrule" align="left">16.0</td>
<td class="Rrule" align="left">9.3</td>
<td class="Rrule" align="left">12.4</td>
<td class="Rrule" align="left">14.1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2">pH 4 / pepsin</td>
<td class="Rrule" align="left">≥ 6.1</td>
<td class="Rrule" align="left">≥ 4.4</td>
<td class="Rrule" align="left">≥ 5.3</td>
<td class="Rrule" align="left">≥ 6.8</td>
<td class="Rrule" align="left">nt</td>
<td class="Rrule" align="left">nt</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">Nanofiltration</td>
<td class="Rrule" align="left">≥ 4.9</td>
<td class="Rrule" align="left">≥ 4.5</td>
<td class="Rrule" align="left">≥ 4.4</td>
<td class="Rrule" align="left">nt</td>
<td class="Rrule" align="left">≥ 7.5</td>
<td class="Rrule" align="left">≥ 5.1</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" colspan="2"><span class="Bold">Overall reduction</span></td>
<td class="Rrule" align="left"><span class="Bold">≥ 26</span></td>
<td class="Rrule" align="left"><span class="Bold">≥ 9</span></td>
<td class="Rrule" align="left"><span class="Bold">≥ 25</span></td>
<td class="Rrule" align="left"><span class="Bold">≥ 16</span></td>
<td class="Rrule" align="left"><span class="Bold">≥ 19</span></td>
<td class="Rrule" align="left"><span class="Bold">≥ 19</span></td>
</tr>
</tbody>
</table>
<p>PRV and the two model viruses for HCV, BVDV and SFV, were inactivated within 1/10, and HIV within 1/2 of the incubation time (pH 4/pepsin treatment) used during production of Carimune<span class="Sup">®</span> NF.</p>
<p>Several of the individual production steps in the Carimune<span class="Sup">®</span> NF manufacturing process have been shown to decrease TSE infectivity of an experimental model agent. TSE reduction steps include precipitation (3.5 logs), depth filtrations (7.3 logs), and nanofiltration (4.4 logs). These studies provide reasonable assurance that low levels of CJD/vCJD agent infectivity, if present in the starting material, would be removed.</p>
<p>The preparation contains at least 96% of IgG and after reconstitution with a neutral unbuffered diluent has a pH of 6.6 ± 0.2. Most of the immunoglobulins are monomeric (7 S) IgG; the remainder consists of dimeric IgG and a small amount of polymeric IgG, traces of IgA and IgM and immunoglobulin fragments.<span class="Sup">22</span>  The distribution of the IgG subclasses corresponds to that of normal serum.<span class="Sup">23-26</span>  Final container lyophilized units are prepared so as to contain 3, 6, or 12 g protein with 1.67 g sucrose and less than 20 mg NaCl per gram of protein. The lyophilized preparation contains no preservative and may be reconstituted with sterile water, 5% dextrose or 0.9% saline to a solution with protein concentrations ranging from 3% to 12% (see <a href="#table4">Table 4</a>). See <a href="#table2">Table 2</a> for calculated Carimune<span class="Sup">®</span> NF <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> (mOsm/kg) at each protein concentration.  The patient's fluid, electrolyte, caloric requirements and renal function should be considered in selecting an appropriate diluent and concentration.</p>
<a name="table2"></a><table width="80%">
<caption><span>Table 2:  Calculated Carimune<span class="Sup">®</span> NF <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">Osmolality</span> (mOsm/kg)</span></caption>
<col align="left" valign="top" width="20%">
<col align="right" valign="top" width="20%">
<col align="right" valign="top" width="20%">
<col align="right" valign="top" width="20%">
<col align="right" valign="top" width="20%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="4">Concentration</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Diluent</th>
<th class="Rrule" align="right">3%</th>
<th class="Rrule" align="right">6%</th>
<th class="Rrule" align="right">9%</th>
<th class="Rrule" align="right">12%</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">0.9% NaCl</td>
<td class="Rrule" align="right">498</td>
<td class="Rrule" align="right">690</td>
<td class="Rrule" align="right">882</td>
<td class="Rrule" align="right">1074</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">5% Dextrose</td>
<td class="Rrule" align="right">444</td>
<td class="Rrule" align="right">636</td>
<td class="Rrule" align="right">828</td>
<td class="Rrule" align="right">1020</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Sterile Water</td>
<td class="Rrule" align="right">192</td>
<td class="Rrule" align="right">384</td>
<td class="Rrule" align="right">576</td>
<td class="Rrule" align="right">768</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Carimune<span class="Sup">®</span> NF contains a broad spectrum of antibody specificities against bacterial, viral, parasitic, and mycoplasma antigens, that are capable of both opsonization and neutralization of microbes and toxins. The 3 week half-life of Carimune<span class="Sup">®</span> NF corresponds to that of Immune Globulin (Human) for intramuscular use, although individual variations in half-life have been observed.<span class="Sup">27,28</span></p>
<p>Appropriate doses of Carimune<span class="Sup">®</span> NF restore abnormally low <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin G</span> levels to the normal range. One hundred percent of the infused dose of IGIV-products is available in the recipient's circulation immediately after infusion. After approximately 6 days, equilibrium is reached between the intra- and extravascular compartments, with <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin G</span> being distributed approximately 50% intravascular and 50% extravascular. In comparison, after the intramuscular injection of immune globulin, the IgG requires 2–5 days to reach its maximum concentration in the intravascular compartment. This concentration corresponds to about 40% of the injected dose.<span class="Sup">28</span></p>
<p>While Carimune<span class="Sup">®</span> NF has been shown to be effective in some cases of Immune <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">Thrombocytopenic Purpura</span> (ITP) (see <span class="Bold"><a href="#IU">INDICATIONS AND USAGE</a></span>), the mechanism of action in ITP has not been fully elucidated. Toxicity from <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has not been observed on regimens of 0.4 g/kg body weight each day for 5 days.<span class="Sup">29-31</span>  Sucrose is added to Carimune<span class="Sup">®</span> NF for reasons of stability and solubility. Since sucrose is excreted unchanged in the urine when given intravenously, Carimune<span class="Sup">®</span> NF may be given to diabetics without compensatory changes in insulin dosage regimen. Please see <span class="Bold"><a href="#Warnings">WARNINGS</a></span> section.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="IU"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span></h2>
<p class="First">Carimune<span class="Sup">®</span> NF is indicated for the maintenance treatment of patients with primary immunodeficiencies (PID), e.g., common variable <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span>, X-linked agammaglobulinemia, severe combined <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span>.<span class="Sup">30,32-34</span>  Carimune<span class="Sup">®</span> NF is preferable to intramuscular Immune Globulin (Human) preparations in treating patients who require an immediate and large increase in the intravascular immunoglobulin level<span class="Sup">28</span>, in patients with limited <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span>, and in patients with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies for whom intramuscular injections are contraindicated. The infusions must be repeated at regular intervals.</p>
<p>Please see <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span> section.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>Immune <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">Thrombocytopenic Purpura</span> (ITP)</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.1"></a><p></p>
<h3>Acute</h3>
<p class="First">A controlled study was performed in children in which Carimune<span class="Sup">®</span> was compared with steroids for the treatment of acute (defined as less than 6 months duration) ITP. In this study sequential platelet levels of 30,000, 100,000, and 150,000/µL were all achieved faster with Carimune<span class="Sup">®</span> than with steroids and without any of the side effects associated with steroids.<span class="Sup">29,35</span>  However, it should be noted that many cases of acute ITP in childhood resolve spontaneously within weeks to months. Carimune<span class="Sup">®</span> has been used with good results in the treatment of acute ITP in adult patients.<span class="Sup">36-38</span>  In a study involving 10 adults with ITP of less than 16 weeks duration, Carimune<span class="Sup">®</span> therapy raised the platelet count to the normal range after a 5 day course. This effect lasted a mean of over 173 days, ranging from 30 to 372 days.<span class="Sup">39</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2"></a><p></p>
<h3>Chronic</h3>
<p class="First">Children and adults with chronic (defined as greater than 6 months duration) ITP have also shown an increase (sometimes temporary) in platelet counts upon administration of Carimune<span class="Sup">®</span>.<span class="Sup">35,39-43</span>  Therefore, in situations that require a rapid rise in platelet count, for example prior to surgery or to control excessive <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, use of Carimune<span class="Sup">®</span> should be considered. In children with chronic ITP, Carimune<span class="Sup">®</span> therapy resulted in a mean rise in platelet count of 312,000/µL with a duration of increase ranging from 2 to 6 months.<span class="Sup">40,43</span>  Carimune<span class="Sup">®</span> therapy may be considered as a means to defer or avoid splenectomy.<span class="Sup">42-44</span>  In adults, Carimune<span class="Sup">®</span> therapy has been shown to be effective in maintaining the platelet count in an acceptable range with or without periodic booster therapy. The mean rise in platelet count was 93,000/µL and the average duration of the increase was 20–24 days.<span class="Sup">39,40</span>  However, it should be noted that not all patients will respond. Even in those patients who do respond, this treatment should not be considered to be curative.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Contra"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Carimune<span class="Sup">®</span> NF is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin.  Individuals with <span class="product-label-link" type="condition" conceptid="433171" conceptname="Selective immunoglobulin A deficiency">IgA deficiency</span>, especially those who have known antibody against IgA, or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to immunoglobulins should only receive Carimune<span class="Sup">®</span> NF with utmost caution due to the risk of severe <span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">immediate hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Immune Globulin Intravenous (Human) (IGIV) products have been reported to be associated with renal dysfunction, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, osmotic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.<span class="Sup">9-14</span></p>
<p>Patients predisposed to <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> include patients with:</p>
<ol>
<li>any degree of pre-existing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span></li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus</li>
<li>age greater than 65</li>
<li><span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span></li>
<li><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span></li>
<li><span class="product-label-link" type="condition" conceptid="441532" conceptname="Monoclonal paraproteinemia">paraproteinemia</span></li>
<li>patients receiving known nephrotoxic drugs</li>
</ol>
<p>In such patients, IGIV products should be administered at the minimum concentration available and the minimum rate of infusion practicable.  While these reports of renal dysfunction and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> have been associated with the use of many of the licensed IGIV products, those containing sucrose as a stabilizer accounted for a disproportionate share of the total number.  Carimune<span class="Sup">®</span> NF contains sucrose.  See <a href="#Precautions">PRECAUTIONS</a> and <a href="#DA">DOSAGE AND ADMINISTRATION</a> sections for important information intended to reduce the risk of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.</p>
<p>IgA deficient patients, especially those with known antibodies against IgA, are at greater risk of developing severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>. </p>
<p>Carimune<span class="Sup">®</span> NF is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and through the application of viral elimination/reduction steps such as alcohol fractionation in the presence of filter aids, nanofiltration and pH 4/pepsin treatment<span class="Sup">19-21</span> (see <a href="#table1">Table 1</a>). Despite these measures, such products may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. There is also the possibility that unknown infectious agents may be present in such products. ALL <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to CSL Behring Pharmacovigilance at 1-866-915-6958. The physician should discuss the risks and benefits of this product with the patient.</p>
<p>Patients with agamma- or extreme <span class="product-label-link" type="condition" conceptid="440072" conceptname="Hypogammaglobulinemia">hypogammaglobulinemia</span> who have never before received immunoglobulin substitution treatment or whose time from last treatment is greater than 8 weeks, may be at risk of developing <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammatory reactions</span> on rapid infusion (greater than 2 mg/kg/min) of Carimune<span class="Sup">®</span> NF. These reactions are manifested by a rise in temperature, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. The patient's vital signs should be monitored continuously. The patient should be carefully observed throughout the infusion, since these reactions on rare occasions may lead to <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. Epinephrine and other appropriate resuscitative drugs and equipment should be available for treatment of an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">acute anaphylactic reaction</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Precautions"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Please see <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span> below, for important information on Carimune<span class="Sup">®</span> NF compatibility with other medications or fluids. Patients should not be volume depleted prior to the initiation of the infusion of IGIV. Periodic monitoring of renal function tests and urine output is particularly important in patients judged to have a potential increased risk for developing <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. Renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, should be assessed prior to the initial infusion of Carimune<span class="Sup">®</span> NF and again at appropriate intervals thereafter. If renal function deteriorates, discontinuation of the product should be considered.  For patients judged to be at risk for developing renal dysfunction, Carimune<span class="Sup">®</span> NF should be infused at a rate less than 2 mg/kg/min.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="IFP"></a><a name="section-7.1"></a><p></p>
<h2>Information for Patients</h2>
<ul>
<li>Instruct patients to immediately report symptoms of decreased urine output, sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>/<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and/or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> (which may suggest kidney damage) to their physicians.</li>
<li>Instruct patients to immediately report symptoms of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>.  These symptoms may include: <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and/or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of an arm or leg with warmth over the affected area, discoloration of an arm or leg, unexplained <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> that worsens on deep breathing, unexplained rapid pulse, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> on one side of the body.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="PreLT"></a><a name="section-7.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">IGIV recipients should be monitored for clinical signs and symptoms of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>. IGIV recipients should be monitored for pulmonary adverse reactions. If Transfusion-Related Acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>) is suspected, appropriate tests should be performed for the presence of anti-neutrophil antibodies in both the product and patient serum. Baseline assessment of blood viscosity should be considered in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.3"></a><p></p>
<h2>Pregnancy Category C</h2>
<p class="First">Animal reproduction studies have not been conducted with Carimune<span class="Sup">®</span> NF. It is also not known whether Carimune<span class="Sup">®</span> NF can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Carimune<span class="Sup">®</span> NF should be given to a pregnant woman only if clearly needed.<span class="Sup">38</span>  Intact immune globulins such as those contained in Carimune<span class="Sup">®</span> NF cross the placenta from maternal circulation increasingly after 30 weeks gestation.<span class="Sup">45,46</span>  In cases of maternal ITP where Carimune<span class="Sup">®</span> was administered to the mother prior to delivery, the platelet response and clinical effect were similar in the mother and neonate.<span class="Sup">38,46-55</span></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.4"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">High dose administration of Carimune<span class="Sup">®</span> in pediatric patients with acute or chronic Immune <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">Thrombocytopenic Purpura</span> did not reveal any pediatric-specific hazard.<span class="Sup">29</span>  Antibodies in Immune Globulin Intravenous (Human) may impair the efficacy of live attenuated viral vaccines such as <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>, and <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>.<span class="Sup">56-58</span>  Immunizing physicians should be informed of recent therapy with Immune Globulin Intravenous (Human) so that appropriate precautions may be taken.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.5"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Carimune<span class="Sup">®</span> NF should be used with caution in patients over 65 years of age and judged to be at increased risk of developing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (see <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>). In the absence of prospective data, recommended doses should not be exceeded and the concentration and infusion rate selected should be the minimum practicable. The product should be infused at a rate less than 2 mg/kg/min.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span> Syndrome</h2>
<p class="First">An <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> syndrome (AMS) has been reported to occur infrequently in association with Immune Globulin Intravenous (Human) (IGIV) treatment. The syndrome usually begins within several hours to two days following IGIV treatment. It is characterized by symptoms and signs including severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">nuchal rigidity</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, painful eye movements, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Cerebrospinal fluid (CSF) studies are frequently positive with <span class="product-label-link" type="condition" conceptid="4240184" conceptname="Pleocytosis">pleocytosis</span>. Patients exhibiting such symptoms and signs should receive a thorough neurological examination, including CSF studies, to rule out other causes of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. AMS may occur more frequently in association with high dose (2 g/kg) IGIV treatment. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span></h2>
<p class="First">Immune Globulin Intravenous (Human) (IGIV) products can contain blood group antibodies which may act as hemolysins and induce <span class="Italics">in vivo</span> coating of red blood cells with immunoglobulin, causing a positive direct antiglobulin reaction and, rarely, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>.<span class="Sup">59-61</span>  <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span> can develop subsequent to IGIV therapy due to enhanced RBC sequestration<span class="Sup">62</span> (see <span class="Bold"><a href="#AR">ADVERSE REACTIONS</a></span>). IGIV recipients should be monitored for clinical signs and symptoms of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> (see <span class="Bold"><a href="#PreLT">PRECAUTIONS: Laboratory Tests</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8"></a><p></p>
<h2>Transfusion-Related Acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>)</h2>
<p class="First">There have been reports of noncardiogenic <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> Transfusion-Related Acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>) in patients administered IGIV.<span class="Sup">63</span>  <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> is characterized by severe <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, normal left ventricular function, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and typically occurs within 1–6 hours after transfusion. Patients with <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> may be managed by using oxygen therapy with adequate ventilatory support.</p>
<p>IVIG recipients should be monitored for pulmonary adverse reactions. If <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> is suspected, appropriate tests should be performed for the presence of anti-neutrophil antibodies in both the product and patient serum (see <span class="Bold"><a href="#PreLT">PRECAUTIONS: Laboratory Tests</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>"></a><a name="section-7.9"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> may occur following treatment with immune globulin products<span class="Sup">1-8</span>, including Carimune NF.  Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors.  <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> may occur in the absence of known risk factors.</p>
<p>Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies.  For patients at risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, administer Carimune NF at the minimum dose and infusion rate practicable.  Ensure adequate hydration in patients before administration.  Monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> and assess blood viscosity in patients at risk for hyperviscosity (see <span class="Bold"><a href="#BOX">BOXED WARNING</a>, <a href="#DA">DOSAGE AND ADMINISTRATION</a>, <a href="#IFP">PRECAUTIONS: Information for Patients</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Increases in creatinine and blood urea nitrogen (BUN) have been observed as soon as one to two days following infusion. Progression to <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, requiring dialysis has been observed. Types of severe renal adverse events that have been seen following IGIV therapy include: <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">acute tubular necrosis</span>, proximal tubular <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> and osmotic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>.<span class="Sup">9-14,64,71–73</span></p>
<p>Inflammatory adverse reactions have been described in agammaglobulinemic and hypogammaglobulinemic patients who have never received immunoglobulin substitution therapy before or in patients whose time from last treatment is greater than 8 weeks and whose initial infusion rate exceeds 2 mg/kg/min.</p>
<p>This occurs in approximately 10% of such cases. Such reactions may also be observed in some patients during chronic substitution therapy. </p>
<p>Reactions, which may become apparent only 30 minutes to 1 hour after the beginning of the infusion, are as follows: <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> of the face, feelings of tightness in the chest, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.  In such cases, the infusion should be slowed or temporarily stopped until the symptoms subside.  The infusion may then be resumed at a lower rate that is comfortable for the patient.  If <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or other severe reactions occur, the infusion should be stopped immediately.</p>
<p><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and transient <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span> or <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>) have also been reported.</p>
<p>Immediate anaphylactoid and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> due to previous sensitization of the recipient to certain antigens, most commonly IgA, may be observed in exceptional cases, described under <span class="Bold"><a href="#Contra">CONTRAINDICATIONS</a></span>.<span class="Sup">30,31,65</span>  In patients with ITP, who receive higher doses (0.4 g/kg/day or greater), 2.9% of infusions may result in adverse reactions.<span class="Sup">21</span>  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, generally mild, is the most common symptom noted, occurring during or following 2% of infusions.  A few cases of usually mild <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> have been reported after infusion of intravenous immunoglobulin products.<span class="Sup">59-61</span>  These were attributed to transferal of blood group (e.g., anti-D) antibodies.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Postmarketing</h2>
<p class="First">The following adverse reactions have been identified and reported during the post-approval use of IGIV products:</p>
<p><span class="Bold Italics">Respiratory</span><br><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span>, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Acute Respiratory Distress Syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>), Transfusion-Related Acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>), <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span><br><span class="Bold Italics">Cardiovascular</span><br><span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vascular collapse</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span><br><span class="Bold Italics">Neurological</span><br><span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span><br><span class="Bold Italics">Integumentary</span><br><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4309632" conceptname="Epidermolysis">epidermolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">bullous dermatitis</span><br><span class="Bold Italics">Hematologic</span><br><span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, positive direct antiglobulin (Coombs) test<br><span class="Bold Italics">General/Body as a Whole</span><br><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span><br><span class="Bold Italics">Musculoskeletal</span><br><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span><br><span class="Bold Italics">Gastrointestinal</span><br>Hepatic dysfunction, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p>
<p>Because postmarketing reporting of these reactions is voluntary and the at-risk populations are of uncertain size, it is not always possible to reliably estimate the frequency of the reaction or establish a causal relationship to exposure to the product. Such is also the case with literature reports authored independently.<span class="Sup">66</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">It is generally advisable not to dilute plasma derivatives with other infusable drugs. Carimune<span class="Sup">®</span> NF should be given by a separate infusion line. No other medications or fluids should be mixed with Carimune<span class="Sup">®</span> NF preparation.</p>
<p>Carimune<span class="Sup">®</span> NF should be used with caution in patients with pre-existing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and in patients judged to be at increased risk of developing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (including, but not limited to those with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, age greater than 65, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, <span class="product-label-link" type="condition" conceptid="441532" conceptname="Monoclonal paraproteinemia">paraproteinemia</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, and patients receiving known nephrotoxic drugs). In these cases especially it is important to assure that patients are not volume depleted prior to Carimune<span class="Sup">®</span> NF infusion. No prospective data are presently available to identify a maximum safe dose, concentration, and rate of infusion in patients determined to be at increased risk of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. In the absence of prospective data, recommended doses should not be exceeded and the concentration and infusion rate selected should be the minimum practicable. For patients judged to be at risk for developing renal dysfunction, Carimune<span class="Sup">®</span> NF should be infused at a rate less than 2 mg/kg/min.</p>
<p>For patients judged to be at an increased risk for <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, a maximum infusion rate of less than 2 mg/kg/min for patients is recommended (see <span class="Bold"><a href="#<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>">PRECAUTIONS: <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></a></span>).</p>
<p>If side effects occur, the infusion should be stopped or slowed until the symptoms subside.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Adult and Child Substitution Therapy</h2>
<p class="First">The recommended dose of Carimune<span class="Sup">®</span> NF in primary <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> is 0.4 to 0.8 g/kg of body weight administered once every three to four weeks by intravenous infusion.</p>
<p>The first infusion of Carimune<span class="Sup">®</span> NF in previously untreated agammaglobulinemic or hypogammaglobulinemic patients must be given as a 3% immunoglobulin solution (see <span class="Bold"><a href="#Reconstitution">Reconstitution</a></span>).  Subsequent infusions may be administered at a higher concentration if the patient shows good tolerance.  </p>
<p>An initial infusion rate of 0.5 mg/kg/min is recommended.  If tolerated, after 30 minutes, the rate may be increased to 1 mg/kg/min for the next 30 minutes.  Thereafter, the rate may be gradually increased in a stepwise manner up to <span class="Bold">a maximum of 3 mg/kg/min</span> as tolerated<span class="Bold">.</span>  Refer to Table 3 for the corresponding infusion rates in mg/kg/min or mL/kg/min for all product concentrations.</p>
<p>The first infusion of Carimune<span class="Sup">®</span> NF in previously untreated agammaglobulinemic and hypogammaglobulinemic patients may lead to systemic side effects.  The nature of these effects has not been fully elucidated.  Some of them may be due to the release of proinflammatory cytokines by activated macrophages in immunodeficient recipients.<span class="Sup">67,68</span>  Subsequent administration of Carimune<span class="Sup">®</span> NF to immunodeficient patients as well as to normal individuals usually does not cause further untoward side effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Therapy of <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">Idiopathic Thrombocytopenic Purpura</span> (ITP)</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2.1"></a><p></p>
<h3>Induction</h3>
<p class="First">The recommended dose of Carimune<span class="Sup">®</span> NF for the treatment of ITP is 0.4 g/kg of body weight on 2–5 consecutive days.  An immunoglobulin solution of 6% (see <span class="Bold"><a href="#Reconstitution">Reconstitution</a></span>) is recommended for use in ITP.</p>
<p>The recommended initial infusion rate for the treatment of ITP is 0.5 mg/kg/min.  If tolerated, after 30 minutes, the rate may be increased to 1 mg/kg/min for the next 30 minutes.  Thereafter, the rate may be gradually increased in a stepwise manner up to <span class="Bold">a maximum of 3 mg/kg/min</span> as tolerated.  Refer to Table 3 for the corresponding infusion rates in mg/kg/min or mL/kg/min for all product concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2.2"></a><p></p>
<h3>Acute ITP – Childhood</h3>
<p class="First">In acute ITP of childhood, if an initial platelet count response to the first two doses is adequate (30–50,000/µL), therapy may be discontinued after the second day of the 5 day course.<span class="Sup">35</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2.3"></a><p></p>
<h3>Maintenance – Chronic ITP</h3>
<p class="First">In adults and children, if after induction therapy the platelet count <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> to less than 30,000/µL and/or the patient manifests clinically significant <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, 0.4 g/kg of body weight may be given as a single infusion. If an adequate response does not result, the dose can be increased to 0.8–1 g/kg of body weight given as a single infusion.<span class="Sup">36,69,70</span></p>
<a name="table3"></a><table width="100%">
<caption><span>Table 3:  Infusion Rates for Carimune<span class="Sup">®</span> NF Concentrations</span></caption>
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="bottom">Concentration<br>(%)</th>
<th class="Rrule" align="center" valign="bottom">Initial Infusion Rate:<br>0.5 mg/kg/min</th>
<th class="Rrule" align="center" valign="bottom">1 mg/kg/min</th>
<th class="Rrule" align="center" valign="bottom">2 mg/kg/min<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center" valign="bottom">Maximum Infusion Rate<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>:<br>3 mg/kg/min </th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Maximum infusion rate for patients at risk of renal dysfunction or <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>For patients <span class="Bold">not</span> at risk of renal dysfunction of <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center"><span class="Bold">3%</span></td>
<td class="Rrule" align="center">0.0167 mL/kg/min</td>
<td class="Rrule" align="center">0.033 mL/kg/min</td>
<td class="Rrule" align="center">0.067 mL/kg/min</td>
<td class="Rrule" align="center">0.10 mL/kg/min</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">6%</span></td>
<td class="Rrule" align="center">0.008 mL/kg/min</td>
<td class="Rrule" align="center">0.0167 mL/kg/min</td>
<td class="Rrule" align="center">0.033 mL/kg/min</td>
<td class="Rrule" align="center">0.050 mL/kg/min</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">9%</span></td>
<td class="Rrule" align="center">0.006 mL/kg/min</td>
<td class="Rrule" align="center">0.011 mL/kg/min</td>
<td class="Rrule" align="center">0.022 mL/kg/min</td>
<td class="Rrule" align="center">0.033 mL/kg/min</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center"><span class="Bold">12%</span></td>
<td class="Rrule" align="center">0.004 mL/kg/min</td>
<td class="Rrule" align="center">0.008 mL/kg/min</td>
<td class="Rrule" align="center">0.016 mL/kg/min</td>
<td class="Rrule" align="center">0.025 mL/kg/min</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Reconstitution"></a><a name="section-9.3"></a><p></p>
<h2>Reconstitution</h2>
<p class="First">(see also <a href="#pictures">pictures</a> next page)</p>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="85%">
<tbody class="Headless">
<tr>
<td align="left">1.</td>
<td align="left">Remove the protective plastic caps from the lyophilisate (LYO) and diluent bottles and disinfect both rubber stoppers with alcohol.  Remove the protective cover from one end of the transfer set and insert the exposed needle through the rubber stopper into the bottle containing the diluent (picture 1).</td>
</tr>
<tr>
<td align="left">2a. and 2b.</td>
<td align="left">Remove the second protective cover from the other end of the transfer set. Grasp both bottles as shown in picture 2a, quickly plunge the diluent bottle onto the lyophilisate bottle and bring the bottles into an upright position. Only if this is done quickly and the bottles are immediately brought into an upright position can the vacuum in the lyophilisate bottle be maintained, thus speeding up reconstitution and facilitating the transfer. Allow the diluent to flow into the lyophilisate bottle (picture 2b).</td>
</tr>
<tr>
<td align="left">3.</td>
<td align="left">Once the appropriate amount of diluent is transferred (see <a href="#table4">Table 4</a>), lift the diluent bottle off the spike to release the vacuum (picture 3).  This will reduce foaming and facilitate dissolution.  Remove the spike.</td>
</tr>
<tr>
<td align="left">4.</td>
<td align="left">Swirl vigorously but do not shake, otherwise a foam will form which is very slow to subside (picture 4).  The lyophilisate dissolves within a few minutes.</td>
</tr>
</tbody>
</table>
<p><a name="pictures"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=610b905a-50d3-48f0-919a-69cc99aab5a8&amp;name=carimune-01.jpg"></p>
<p>To reconstitute Carimune<span class="Sup">®</span> NF from the individual vial package, or when using other diluents or higher concentrations, Table 4 indicates the volume of sterile diluent required. Observing aseptic technique, this volume should be drawn into a sterile hypodermic syringe and needle. The diluent is then injected into the corresponding Carimune<span class="Sup">®</span> NF vial size.</p>
<a name="table4"></a><table width="70%">
<caption><span>Table 4:  Required Diluent Volume<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></span></caption>
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Target Concentration</th>
<th class="Rrule" align="center">3 g Vial</th>
<th class="Rrule" align="center">6 g Vial</th>
<th class="Rrule" align="center">12 g Vial</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>In patients judged to be at increased risk of developing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>, the concentration and infusion rate of Carimune<span class="Sup">®</span> NF should be the minimum practicable.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>Container not large enough to permit this concentration.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="center">3%</td>
<td class="Rrule" align="center">100 mL</td>
<td class="Rrule" align="center">200 mL</td>
<td class="Rrule" align="center"><a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">6%</td>
<td class="Rrule" align="center">50 mL</td>
<td class="Rrule" align="center">100 mL</td>
<td class="Rrule" align="center">200 mL</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">33 mL</td>
<td class="Rrule" align="center">66 mL</td>
<td class="Rrule" align="center">132 mL</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">12%</td>
<td class="Rrule" align="center">25 mL</td>
<td class="Rrule" align="center">50 mL</td>
<td class="Rrule" align="center">100 mL</td>
</tr>
</tbody>
</table>
<p>If large doses of Carimune<span class="Sup">®</span> NF are to be administered, several reconstituted vials of identical concentration and diluent may be pooled in an empty sterile glass or plastic i.v. infusion container using aseptic technique.</p>
<p>Carimune<span class="Sup">®</span> NF normally dissolves within a few minutes, though in exceptional cases it may take up to 20 minutes.</p>
<p><span class="Bold">DO NOT SHAKE!  Excessive <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> will cause foaming.</span></p>
<p>Any undissolved particles should respond to careful rotation of the bottle. Avoid foaming. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Filtering of Carimune<span class="Sup">®</span> NF is acceptable but not required. Pore sizes of 15 microns or larger will be less likely to slow infusion, especially with higher Carimune<span class="Sup">®</span> NF concentrations. Antibacterial filters (0.2 microns) may be used. When reconstitution of Carimune<span class="Sup">®</span> NF occurs outside of sterile laminar air flow conditions, administration must begin promptly with partially used vials discarded. When reconstitution is carried out in a sterile laminar flow hood using aseptic technique, administration may begin within 24 hours provided the solution has been refrigerated during that time. Do not freeze Carimune<span class="Sup">®</span> NF solution.</p>
<p><span class="Bold">PROCEED WITH INFUSION ONLY IF SOLUTION IS CLEAR AND AT APPROXIMATELY ROOM TEMPERATURE.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Carimune<span class="Sup">®</span> NF is available as a white lyophilized powder in 3, 6 and 12 g size vials. The only diluents which may be used to reconstitute the product are sterile (0.9%) Sodium Chloride Injection USP, 5% Dextrose, or Sterile Water.</p>
<p>Each product presentation includes a package insert and the following components:</p>
<table width="85%">
<col align="center" valign="top" width="20%">
<col align="center" valign="middle" width="20%">
<col align="left" valign="middle" width="60%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Presentation</th>
<th class="Rrule" align="center">Carton<br>NDC Number</th>
<th class="Rrule" align="center">Components</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">3 g</td>
<td class="Rrule" align="center">44206-416-03</td>
<td class="Rrule" align="left"><ul class="Disc">
<li>Carimune NF in a single-use vial [NDC 44206-416-90]</li>
<li>One double-ended transfer spike for reconstitution</li>
</ul></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">6 g</td>
<td class="Rrule" align="center">44206-417-06</td>
<td class="Rrule" align="left"><ul class="Disc">
<li>Carimune NF in a single-use vial [NDC 44206-417-91]</li>
<li>One double-ended transfer spike for reconstitution</li>
</ul></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">12 g</td>
<td class="Rrule" align="center">44206-418-12</td>
<td class="Rrule" align="left"><ul class="Disc">
<li>Carimune NF in a single-use vial [NDC 44206-418-92]</li>
<li>One double-ended transfer spike for reconstitution</li>
</ul></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<h2>Storage and Handling</h2>
<ul class="Disc">
<li>Carimune<span class="Sup">®</span> NF should be stored at room temperature not exceeding 30°C (86°F).</li>
<li>The preparation should not be used after the expiration date printed on the label.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Dalakas MC:  High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>. Neurology 1994; 44:223–226.</li>
<li>Caress JB, Cartwright MS, Donofrio PD, Peacock JE:  The clinical features of 16 cases of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> associated with administration of IVIg. Neurology 2003; 60:1822–1824.</li>
<li>Woodruff RK, Grigg AP, Firkin FC, Smith IL:  Fatal thrombotic events during treatment of <span class="product-label-link" type="condition" conceptid="4028065" conceptname="Autoimmune thrombocytopenia">autoimmune thrombocytopenia</span> with intravenous immunoglobulin in elderly patients. Lancet 1986; 2:217–218.</li>
<li>Jordan S, Cunningham-Rundles C, McEwan R:  Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 2003; 3:653–664.</li>
<li>Wolberg AS, Kon RH, Monroe DM, Hoffman M:  Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000; 65:30–34.</li>
<li>Zaidan R, Al Moallem M, Wani BA, Shameena AR, Al Tahan AR, Daif AK, Al Rajeh S:  <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> complicating high dose intravenous immunoglobulin: report of three cases and review of the literature. Eur J Neurology 2003; 10:367–372.</li>
<li>Okuda D, Flaster M, Frey J, Sivakumar, K:  <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">Arterial thrombosis</span> induced by IVIg and its treatment with tPA. Neurology 2003; 60:1825–1826.</li>
<li>Dalakas MC, Clark WM:  <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Strokes</span>, <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>, and IVIg. Rare incidents blemish an excellent safety record. Neurology 2003; 60:1736–1737.</li>
<li>Winward DB, Brophy MT:  <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> after administration of intravenous immunoglobulin: Review of the literature and case report. Pharmacotherapy 1995; 15:765–772.</li>
<li>Cantú TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel P:  <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> associated with immunoglobulin therapy. Am J Kidney Dis 1995; 25:228–234.</li>
<li>Cayco AV, Perazella MA, Hayslett JP:  <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal insufficiency</span> after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Amer Soc Nephrology 1997; 8:1788–1793.</li>
<li>Rault R, Piraino B, Johnston JR, Oral A:  Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 1991, 36:83–86.</li>
<li>Michail S, Nakopoulou L, Stravrianopoulos I, Stamatiadis D, Avdikou K, Vaiopoulos G, Stathakis C:  <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> associated with immunoglobulin administration. Nephrol Dial Transplant 1997; 12:1497–99.</li>
<li>Ashan N, Wiegand LA, Abendroth CS, Manning EC:  <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> following immunoglobulin therapy. Am J Nephrol 1996; 16:532–6.</li>
<li>Gardi A:  Quality control in the production of an immunoglobulin for intravenous use. Blut 1984; 48:337–344.</li>
<li>Römer J, Morgenthaler JJ, Scherz R, et al:  Characterization of various immunoglobulin-preparations for intravenous application. I. Protein composition and antibody content. Vox Sang 1982; 42:62–73.</li>
<li>Römer J, Späth PJ, Skvaril F, et al:  Characterization of various immunoglobulin preparations for intravenous application. II. Complement activation and binding to Staphylococcus protein A. Vox Sang 1982; 42:74–80.</li>
<li>Gregori L, Maring JA, MacAuley C et al:  Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals 2004; 32:1–10.</li>
<li>Omar A, and Kempf C:  Removal of neutralized model Parvoviruses and Enteroviruses in human IgG solutions by nanofiltration. Transfusion 2002; 42:1005–1010.</li>
<li>Späth P, Kempf C, and Gold R:  Herstellung, Verträglichkeit und Virussicherheit von intravenösem Immunglobulin. In "Immunglobuline in der Neurobiologie" (P. Berlit, ed.), Steinkopff Verlag, Darmstadt, BRD 2001, pp 1–42.</li>
<li>Kempf C, Morgenthaler JJ, Rentsch M, and Omar A:  Viral safety and manufacturing of an intravenous immunoglobulin. In "Intravenous Immunoglobulin Research and Therapy" Kazatchkine and Morell, eds. Parthenon Publishing Group. 1996, pp 11–18.</li>
<li>Römer J, Späth PJ:  Molecular composition of immunoglobulin preparations and its relation to complement activation, in Nydegger UE (ed): Immunohemotherapy: A Guide to Immunoglobulin Prophylaxis and Therapy. London, Academic Press 1981, pp 123–130.</li>
<li>Skvaril F, Roth-Wicky B, and Barandun S:  IgG subclasses in human-g-globulin preparations for intravenous use and their reactivity with Staphylococcus protein A. Vox Sang 1980; 38:147.</li>
<li>Skvaril F:  Qualitative and quantitative aspects of IgG subclasses in i.v. immunoglobulin preparations, in Nydegger UE (ed): Immunohemotherapy: A Guide to Immunoglobulin Prophylaxis and Therapy. London, Academic Press, 1981, pp 113–122.</li>
<li>Skvaril F, and Barandun S:  In vitro characterization of immunoglobulins for intravenous use, in Alving BM, Finlayson JS (eds): Immunoglobulins: Characteristics and Uses of Intravenous Preparations, DHHS Publication No. (FDA)-80-9005. US Government Printing Office, 1980, pp 201–206.</li>
<li>Burckhardt JJ, Gardi A, Oxelius V, et al:  <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">Immunoglobulin G</span> subclass distribution in three human intravenous immunoglobulin preparations. Vox Sang 1989; 57:10–14.</li>
<li>Morell A, and Skvaril F:  Struktur und biologische Eigenschaften von Immunglobulinen und g-Globulin-Präparaten. II. Eigenschaften von g-Globulin-Präparaten. Schweiz Med Wochenschr 1980; 110:80.</li>
<li>Morell A, Schürch B, Ryser D, et al:  In vivo behaviour of gamma globulin preparations. Vox Sang 1980; 38:272.</li>
<li>Imbach P, Barandun S, d'Apuzzo V, et al:  High-dose intravenous gamma globulin for <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span> in childhood. Lancet 1981; 1:1228.</li>
<li>Barandun S, Morell A, Skvaril F: Clinical experiences with immunoglobulin for intravenous use, in Alving BM, Finlayson JS (eds):  Immunoglobulins: Characteristics and Uses of Intravenous Preparations. DHHS Publication No. (FDA)-80-9005. US Government Printing Office, 1980, pp 31–35.</li>
<li>Schiff R, Sedlak D, Buckley R:  Rapid infusion of Sandoglobulin™ in patients with primary humoral <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span>. J <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> Clin Immunol 88:61, 1991.</li>
<li>Joller PW, Barandun S, Hitzig WH:  Neue Möglichkeiten der Immunglobulin-Ersatztherapie bei Antikörpermangel-Syndrom. Schweiz Med Wochenschr 1980; 110:1451.</li>
<li>Barandun S, Imbach P, Morell A, et al:  Clinical indications for immunoglobulin infusion, in Nydegger UE (ed):  Immunohemotherapy: A Guide to Immunoglobulin Prophylaxis and Therapy. London, Academic Press, 1981, pp 275–282.</li>
<li>Cunningham-Rundles C, Smithwick EM, Siegal FP, et al:  Treatment of primary humoral <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> disease with intravenous (pH 4.0 treated) gamma globulin, in Nydegger UE (ed): Guide to Immunoglobulin Prophylaxis and Therapy. London, Academic Press, 1981, pp 283–290.</li>
<li>Imbach P, Wagner HP, Berchtold W, et al:  Intravenous immunoglobulin versus oral corticosteroids in acute immune <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span> in childhood. Lancet 1985; 2:464.</li>
<li>Fehr J, Hofmann V, Kappeler U:  Transient reversal of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span> by high-dose intravenous gamma globulin. N Engl J Med 1982; 306:1254.</li>
<li>Müller-Eckhardt C, Küenzlen E, Thilo-Körner D, et al:  High-dose intravenous immunoglobulin for posttransfusion <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>. N Engl J Med 1983; 308:287.</li>
<li>Wenske G, Gaedicke G, Küenzlen E, et al:  Treatment of <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span> in pregnancy by high-dose intravenous immunoglobulin. Blut 1983; 46:347–353.</li>
<li>Newland AC, Treleaven JG, Minchinton B, et al:  High-dose intravenous IgG in adults with <span class="product-label-link" type="condition" conceptid="4028065" conceptname="Autoimmune thrombocytopenia">autoimmune thrombocytopenia</span>. Lancet 1983; 1:84–87.</li>
<li>Bussel JB, Kimberly RP, Inman RD, et al:  Intravenous gammaglobulin for chronic <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span>. Blood 1983; 62:480–486.</li>
<li>Abe T, Matsuda J, Kawasugi K, et al:  Clinical effect of intravenous immunoglobulin in chronic <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span>. Blut 1983; 47:69–75.</li>
<li>Bussel JB, Schulman I, Hilgartner MW, et al:  Intravenous use of gamma globulin in the treatment of chronic immune <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span> as a means to defer splenectomy. J Pediatr 1983; 103:651–654.</li>
<li>Imholz B, et al:  Intravenous immunoglobulin (i.v. IgG) for previously treated acute or for chronic <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span> (ITP) in childhood: A prospective multicenter study. Blut 1988; 56:63–68.</li>
<li>Lusher JM, and Warrier I:  Use of intravenous gamma globulin in children with <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span> and other immune <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenias</span>. Am J Med 1987; 83 (suppl 4A):10–16.</li>
<li>Hammarstrom L, and Smith CI:  Placental transfer of intravenous immunoglobulin. Lancet 1986; 1:681.</li>
<li>Sidiropoulos D, et al:  Transplacental passage of intravenous immunoglobulin in the last trimester of pregnancy. J Pediatr 1986; 109:505–508.</li>
<li>Wenske G, et al:  <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">Idiopathic thrombocytopenic purpura</span> in pregnancy and neonatal period. Blut 1984; 48:377–382.</li>
<li>Fabris P, et al:  Successful treatment of a steroid-resistant form of <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span> in pregnancy with high doses of intravenous immunoglobulins. Acta Haemat 1987; 77:107–110.</li>
<li>Coller BS, et al:  Management of severe ITP during pregnancy with intravenous immunoglobulin (IVIgG). Clin Res 1985; 33:545A.</li>
<li>Tchernia G, et al:  Management of immune <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in pregnancy: Response to infusions of immunoglobulins. Am J Obstet Gynecol 1984; 148:225–226.</li>
<li>Newland AC, et al:  Intravenous IgG for <span class="product-label-link" type="condition" conceptid="4028065" conceptname="Autoimmune thrombocytopenia">autoimmune thrombocytopenia</span> in pregnancy. N Engl J Med 1984; 310:261–262.</li>
<li>Morgenstern GR, et al:  <span class="product-label-link" type="condition" conceptid="4028065" conceptname="Autoimmune thrombocytopenia">Autoimmune thrombocytopenia</span> in pregnancy: New approach to management. Br Med J 1983; 287:584.</li>
<li>Ciccimarra F, et al:  Treatment of neonatal passive immune <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. J Pediat 1984; 105:677–678.</li>
<li>Rose VL, and Gordon LI:  <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">Idiopathic thrombocytopenic purpura</span> in pregnancy. Successful management with immunoglobulin infusion. JAMA 1985; 254:2626–2628.</li>
<li>Gounder MP, et al:  Intravenous gammaglobulin therapy in the management of a patient with <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span> and a warm autoimmune erythrocyte panagglutinin during pregnancy. Obstet Gynecol 1986; 67:741–746.</li>
<li>Siber GR, Werner BG, Halsey NA, et al:  Interference of immune globulin with <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> and <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span> immunisation. J Pediatr 1993; 122:204–211.</li>
<li>American Academy of Pediatrics, Committee on Infectious Diseases:  Recommended timing of routine <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> immunization for children who have recently received immune globulin preparations. Pediatrics 1994; 93:682–685.</li>
<li>Centers of Disease Control and Prevention. <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">Measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>, and <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>-vaccine use and strategies for elimination of <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>, and congenital <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span> syndrome and control of <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>: recommendations of the advisory committee on immunization practices (ACIP). MMWR, Morbidity and Mortality Weekly Report. May 22, 1998; vol 47/No. RR-8, 1–57.</li>
<li>Copelan EA, Strohn PL, Kennedy MS, Tutschka PJ:  <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span> following intravenous immune globulin therapy. Transfusion 1986; 26:410–412.</li>
<li>Thomas MJ, Misbah SA, Chapel HM, Jones M, Elrington G, Newsom-Davis J:  <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span> after high-dose intravenous Ig. Blood 1993; 15:3789.</li>
<li>Wilson JR, Bhoopalam N, Fisher M. <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span> associated with intravenous immunoglobulin. Muscle &amp; Nerve 1997; 20:1142–1145.</li>
<li>Kessary-Shoham H, Levy Y, Shoenfeld Y, Lorber M, Gershon H:  <span class="Italics">In vivo</span> administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J Autoimmun 1999; 13:129–135.</li>
<li>Rizk A, Gorson KC, Kenney L, Weinstein R:  Transfusion-related acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">lung injury</span> after the infusion of IVIG. Transfusion 2001; 41:264–268.</li>
<li>Phillips AO: <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> and intravenous immunoglobulin [letter; comment]. Clin Nephrol 1992; 37:217.</li>
<li>Cunningham-Rundles C, Day NK, Wahn V, et al: Reactions to intravenous gamma globulin infusions and immune complex formation, in Nydegger UE (ed):  Immunohemotherapy: A Guide to Immunoglobulin Prophylaxis and Therapy. London, Academic Press, 1981, pp 447–449.</li>
<li>Pierce LR, Jain N:  Risks associated with the use of intravenous immunoglobulin. Trans Med Rev 2003; 17:241–251.</li>
<li>Aukrust P, Froland SS, Liabakk N-B, Müller F., et al:  Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration <span class="Italics">in vivo</span>. Blood 1994; 84:2136–2143.</li>
<li>Bagdasarian A, Tonetta S, Harel W, Mamidi R., Uemura Y:  IVIG adverse reactions: potential role of cytokines and vasoactive substances. Vox Sang 1998; 74:74–82.</li>
<li>Bussel JB, Pham LC, Hilgartner MW, et al:  Long-term maintenance of adults with ITP using intravenous gamma globulin. Abstract, American Society of Hematology. New Orleans, December, 1985.</li>
<li>Imbach PA, Kühne T, Holländer G:  Immunologic aspects in the pathogenesis and treatment of immune <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span> in children. Current opinion in Pediatrics 1997; 9:35–40.</li>
<li>Anderson W, Bethea W:  Renal lesions following administration of hypertonic solutions of sucrose. JAMA 1940; 114:1983–1987.</li>
<li>Lindberg H, Wald A:  Renal lesions following the administration of hypertonic solutions: Arch Intern Med 1939; 63:907–918.</li>
<li>Rigdon RH, Cardwell ES:  Renal lesions following the intravenous injection of hypertonic solution of sucrose: A clinical and experimental study. Arch Intern Med 1942; 69:670–690.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First">Manufactured by:<br><span class="Bold">CSL Behring AG</span><br>Bern, Switzerland<br>US License No. 1766</p>
<p>Distributed by:<br><span class="Bold">CSL Behring LLC</span><br>Kankakee, IL 60901 USA</p>
<p>Revised: September 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>Principal Display Panel - 3 g Vial Carton</h1>
<p class="First"><span class="Bold">NDC 44206-416-03</span></p>
<p><span class="Bold">3 g</span></p>
<p><span class="Bold">Immune Globulin<br>Intravenous (Human)</span></p>
<p><span class="Bold">CARIMUNE<span class="Sup">®</span> NF<br>Nanofiltered</span></p>
<p>3 Grams lyophilized<br>(single use vial)</p>
<p><span class="Bold">For intravenous administration<br>Rx only</span></p>
<p><span class="Bold">CSL Behring</span></p>
<div class="Figure"><img alt="Principal Display Panel - 3 g Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=610b905a-50d3-48f0-919a-69cc99aab5a8&amp;name=carimune-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>Principal Display Panel - 6 g Vial Carton</h1>
<p class="First"><span class="Bold">NDC 44206-417-06</span></p>
<p><span class="Bold">6 g</span></p>
<p><span class="Bold">Immune Globulin<br>Intravenous (Human)</span></p>
<p><span class="Bold">CARIMUNE<span class="Sup">®</span> NF<br>Nanofiltered</span></p>
<p>6 Grams lyophilized<br>(single use vial)</p>
<p><span class="Bold">For intravenous administration<br>Rx only</span></p>
<p><span class="Bold">CSL Behring</span></p>
<div class="Figure"><img alt="Principal Display Panel - 6 g Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=610b905a-50d3-48f0-919a-69cc99aab5a8&amp;name=carimune-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>Principal Display Panel - 12 g Vial Carton</h1>
<p class="First"><span class="Bold">NDC 44206-418-12</span></p>
<p><span class="Bold">12 g</span></p>
<p><span class="Bold">Immune Globulin<br>Intravenous (Human)</span></p>
<p><span class="Bold">CARIMUNE<span class="Sup">®</span> NF<br>Nanofiltered</span></p>
<p>12 Grams lyophilized<br>(single use vial)</p>
<p><span class="Bold">For intravenous administration<br>Rx only</span></p>
<p><span class="Bold">CSL Behring</span></p>
<div class="Figure"><img alt="Principal Display Panel - 12 g Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=610b905a-50d3-48f0-919a-69cc99aab5a8&amp;name=carimune-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARIMUNE  		
					NANOFILTERED</strong><br><span class="contentTableReg">human <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin g</span> injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:44206-416</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HUMAN <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">IMMUNOGLOBULIN G</span></strong> (HUMAN <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">IMMUNOGLOBULIN G</span>) </td>
<td class="formItem">HUMAN <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">IMMUNOGLOBULIN G</span></td>
<td class="formItem">3 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sucrose</strong></td>
<td class="formItem">5 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:44206-416-03</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:44206-416-90</td>
<td class="formItem">1  in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA102367</td>
<td class="formItem">02/10/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARIMUNE  		
					NANOFILTERED</strong><br><span class="contentTableReg">human <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin g</span> injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:44206-417</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HUMAN <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">IMMUNOGLOBULIN G</span></strong> (HUMAN <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">IMMUNOGLOBULIN G</span>) </td>
<td class="formItem">HUMAN <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">IMMUNOGLOBULIN G</span></td>
<td class="formItem">6 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sucrose</strong></td>
<td class="formItem">10 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:44206-417-06</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:44206-417-91</td>
<td class="formItem">1  in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA102367</td>
<td class="formItem">02/10/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARIMUNE  		
					NANOFILTERED</strong><br><span class="contentTableReg">human <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin g</span> injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:44206-418</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HUMAN <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">IMMUNOGLOBULIN G</span></strong> (HUMAN <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">IMMUNOGLOBULIN G</span>) </td>
<td class="formItem">HUMAN <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">IMMUNOGLOBULIN G</span></td>
<td class="formItem">12 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sucrose</strong></td>
<td class="formItem">20 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:44206-418-12</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:44206-418-92</td>
<td class="formItem">1  in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA102367</td>
<td class="formItem">02/10/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>CSL Behring AG
							(481152762)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">CSL Behring AG</td>
<td class="formItem"></td>
<td class="formItem">481152762</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>14c69ccf-9b5a-414d-9a01-f06d0bb1d398</div>
<div>Set id: 610b905a-50d3-48f0-919a-69cc99aab5a8</div>
<div>Version: 8</div>
<div>Effective Time: 20131002</div>
</div>
</div> <div class="DistributorName">CSL Behring AG</div></p>
</body></html>
